Director Kenneth L. Gayron filed a Form 4 with the SEC on November 18, 2026, disclosing the acquisition of stock options to purchase common stock of Research Solutions, Inc. (NASDAQ:RSSS), with a transaction date of November 16, 2026.
Key Highlights
- Option grant: Gayron received options to purchase 12,500 shares of common stock on November 16, 2026.
- Exercise price: The options carry an exercise price of $1.89 per share.
- Acquisition price: The options were acquired at a price of $0, according to the filing.
- Expiration date: The options expire on November 15, 2036.
- Post-transaction holdings: Gayron beneficially owns 12,500 derivative securities following the reported transaction.
- Vesting schedule: One-third of the options vest on November 16, 2027, with 1/12th vesting on the last day of each quarter beginning December 31, 2027 until fully vested.
Research Solutions Director Gayron Receives Options Under Multi-Year Vesting Plan
According to the Form 4 filing, Kenneth L. Gayron, identified as a director of Research Solutions, Inc., acquired options to purchase 12,500 shares of the company's common stock on November 16, 2026. The transaction was recorded with an acquisition code of "A" in Table II, covering derivative securities. The exercise price of the options is listed as $1.89, and the price of the derivative security at acquisition is reported as $0.
The filing discloses that the options are subject to a multi-year vesting schedule. As stated in the explanation of responses, "1/3rd of the options vest on November 16, 2027 and 1/12th of the options vest on the last day of each quarter beginning December 31, 2027 until fully vested." The options carry an expiration date of November 15, 2036, giving them a ten-year term from the transaction date. Ownership of the derivative securities is reported as direct.
The form was filed by one reporting person and was signed by David Kutil as attorney-in-fact on November 18, 2026. The filing does not indicate that the transaction was made pursuant to a Rule 10b5-1(c) plan, as the relevant checkbox was not marked. No non-derivative securities transactions were reported in Table I.
What Was Disclosed
Research Solutions, Inc. director Kenneth L. Gayron disclosed the grant of options to purchase 12,500 shares of common stock at an exercise price of $1.89, acquired on November 16, 2026, with an expiration of November 15, 2036 and a graduated vesting schedule beginning in 2027.



Please wait processing your request...